The alleviative effect of C-phycocyanin peptides against TNBS-induced inflammatory bowel disease in zebrafish via the MAPK/Nrf2 signaling pathways

Xu, Fenghua; Yang, Fei; Qiu, Yuezi; Wang, Chuansen; Zou, Qinglin; Wang, Lizhen; Li, Xiaobin; Jin, Meng; Liu, Kechun; Zhang, Shanshan; Zhang, Yun; Li, Bing

doi:10.1016/j.fsi.2023.109351

Cited by 6 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among six peptides which are disclosed in the China patent (Patent NO: 202010313278X), LLTRAGL showed positive anti-inflammatory activities without obvious side effects on zebrafish. Furthermore, in a recent study, it was proved that the anti-inflammatory peptides derived from food-resource phycocyanin had better anti-IBD activity [ 19 ]. This study provides a possibility for the study of the same food-derived anti-inflammatory peptides in anti-IBD with safety and effectiveness.…”

Section: Introductionmentioning

confidence: 99%

The Peptide LLTRAGL Derived from Rapana venosa Exerts Protective Effect against Inflammatory Bowel Disease in Zebrafish Model by Regulating Multi-Pathways

Cao,

Xu,

Xia

et al. 2024

Marine Drugs

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic inflammatory bowel disease with unknown pathogenesis which has been gradually considered a public health challenge worldwide. Peptides derived from Rapana venosa have been shown to have an anti-inflammatory effect. In this study, peptide LLTRAGL derived from Rapana venosa was prepared by a solid phase synthesis technique. The protective effects of LLTRAGL were studied in a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced zebrafish colitis model. The underlying mechanisms of LLTRAGL were predicted and validated by transcriptome, real-time quantitative PCR assays and molecular docking. The results showed that LLTRAGL reduced the number of macrophages migrating to the intestine, enhanced the frequency and rate of intestinal peristalsis and improved intestinal inflammatory damage. Furthermore, transcriptome analysis indicated the key pathways (NOD-like receptor signal pathway and necroptosis pathway) that link the underlying protective effects of LLTRAGL’s molecular mechanisms. In addition, the related genes in these pathways exhibited different expressions after TNBS treatment. Finally, molecular docking techniques further verified the RNA-sequencing results. In summary, LLTRAGL exerted protective effects in the model of TNBS-induced colitis zebrafish. Our findings provide valuable information for the future application of LLTRAGL in IBD.

show abstract

Section: Introductionmentioning

confidence: 99%

The Peptide LLTRAGL Derived from Rapana venosa Exerts Protective Effect against Inflammatory Bowel Disease in Zebrafish Model by Regulating Multi-Pathways

Cao,

Xu,

Xia

et al. 2024

Marine Drugs

Self Cite

View full text Add to dashboard Cite

show abstract

The potential of zebrafish as drug discovery research tool in immune-mediated inflammatory disease

Smith

2024

Inflammopharmacol

View full text Add to dashboard Cite

Immune-mediated inflammatory disease (IMID) prevalence is estimated at 3–7% for Westernised populations, with annual incidence reported at almost 1 in 100 people globally. More recently, drug discovery approaches have been evolving towards more targeted therapies with an improved long-term safety profile, while the requirement for individualisation of medicine in complex conditions such as IMIDs, is acknowledged. However, existing preclinical models—such as cellular and in vivo mammalian models—are not ideal for modern drug discovery model requirements, such as real-time in vivo visualisation of drug effects, logistically feasible safety assessment over the course of a lifetime, or dynamic assessment of physiological changes during disease development. Zebrafish share high homology with humans in terms of proteins and disease-causing genes, with high conservation of physiological processes at organ, tissue, cellular and molecular level. These and other unique attributes, such as high fecundity, relative transparency and ease of genetic manipulation, positions zebrafish as the next major role player in IMID drug discovery. This review provides a brief overview of the suitability of this organism as model for human inflammatory disease and summarises the range of approaches used in zebrafish-based drug discovery research. Strengths and limitations of zebrafish as model organism, as well as important considerations in research study design, are discussed. Finally, under-utilised avenues for investigation in the IMID context are highlighted.

show abstract

Nutritional mitigation of heatwave stress in European seabass, Dicentrarchus labrax: Metabolic, cellular, and molecular responses

Islam,

Puebla,

Kunzmann

2024

Aquaculture Reports

View full text Add to dashboard Cite

The alleviative effect of C-phycocyanin peptides against TNBS-induced inflammatory bowel disease in zebrafish via the MAPK/Nrf2 signaling pathways

Cited by 6 publications

References 60 publications

The Peptide LLTRAGL Derived from Rapana venosa Exerts Protective Effect against Inflammatory Bowel Disease in Zebrafish Model by Regulating Multi-Pathways

The Peptide LLTRAGL Derived from Rapana venosa Exerts Protective Effect against Inflammatory Bowel Disease in Zebrafish Model by Regulating Multi-Pathways

The potential of zebrafish as drug discovery research tool in immune-mediated inflammatory disease

Nutritional mitigation of heatwave stress in European seabass, Dicentrarchus labrax: Metabolic, cellular, and molecular responses

Contact Info

Product

Resources

About